SCHEMBL23065136

SCHEMBL23065136

Cc1ccc2nc(Nc3ccccc3)n(-c3cccnc3)c(=O)c2c1

nearest known ligand 0.59

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.55
ALOX12 P18054 1/20 0.54
PSD A5PKW4 1/20 0.48
MAPT P10636 4/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.43
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29623220 1.00 MDM2 (0.55) MDM2ALOX12PSDMAPTMEN1
SCHEMBL30103264 0.93 MDM2 (0.49) MDM2ALOX12PSDMAPTKMT2A
SCHEMBL23958215 0.93 MDM2 (0.49) MDM2ALOX12PSDMAPTKMT2A
SCHEMBL29623145 0.87 ALDH1A1 (0.48) MDM2ALOX12RAB9A
SCHEMBL24089900 0.87 ALDH1A1 (0.48) MDM2ALOX12RAB9A
SCHEMBL24090095 0.87 PIK3CD (0.50) MDM2ALOX12MAPTKDM4ERAB9A
SCHEMBL24090110 0.86 G6PD (0.48) MDM2ALOX12MEN1KMT2ASMN1; SMN2
SCHEMBL23958124 0.86 MDM2 (0.51) MDM2ALOX12PSDMAPTKDM4E
SCHEMBL23065259 0.82 ALDH1A1 (0.48) MDM2ALOX12
SCHEMBL23958245 0.82 PIK3CD (0.50) MDM2ALOX12KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11352366-B2 2-aminoquinazolinone derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-06-07 US disclosed
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-05-12 US disclosed
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2021-12-09 US disclosed
WO-2021039968-A1 2-AMINOQUINAZOLINONE DERIVATIVE 大日本住友製薬株式会社 2021-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220143020-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, CRKL MDM2 4282/4885ALOX12 3008/4885PSD 4617/4885
US-20210380598-A1 2-AMINOQUINAZOLINONE DERIVATIVE CNKSR1, HAX1, SLC26A3 MDM2 4138/4885ALOX12 3295/4885PSD 4587/4885
US-11352366-B2 2-aminoquinazolinone derivative CNKSR1, HAX1, SLC26A3 MDM2 4138/4885ALOX12 3295/4885PSD 4587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.